Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association Between Pathologic Response and Survival Following Neoadjuvant Targeted Therapy in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery - 2 Aug 2025

Dai Chenyang, Yang Xiaodong, Yang Delun, An Zhao, Xie Huikang, Zhao Shengnan, Wu Chunyan, Zhao Deping, Chen Chang

Abstract excerpt

OBJECTIVES: The International Association for the Study of Lung Cancer (IASLC) recommended applying a 10% residual viable tumour (%RVT) threshold for major pathological response (MPR) to all therapies. However, evidence supporting the association between pathological regression and prognosis after neoadjuvant targeted therapy is lacking. METHODS: This study retrospectively included 228 patients with epidermal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Neoadjuvant Therapy

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 40758475
DOI: 10.1093/ejcts/ezaf269

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association Between Pathologic Response and Survival Following Neoadjuvant Targeted Therapy in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.PMID 40758475Read ↗

Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review.Semantic proximity Read ↗

Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapySemantic proximity Read ↗

Computed Tomography-derived intratumoral and peritumoral radiomics in predicting EGFR mutation in lung adenocarcinoma.Semantic proximity Read ↗

Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations.Semantic proximity Read ↗

Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.Semantic proximity Read ↗

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.Semantic proximity Read ↗

Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery.Semantic proximity Read ↗

Machine Learning–Based Prediction of Recurrence After Curative Resection in Non–Small Cell Lung CancerSemantic proximity Read ↗

Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.Semantic proximity Read ↗

Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.Semantic proximity Read ↗

Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.